Alan Menter

Summary

Affiliation: Baylor University Medical Center
Country: USA

Publications

  1. ncbi request reprint Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    Int J Dermatol 46:637-48. 2007
  2. ncbi request reprint The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 54:61-3. 2006
  3. ncbi request reprint Update on botulinum toxin for facial aesthetics
    Jennifer Clay Cather
    Texas Dermatology Research Institute, Baylor Medical University, Dallas, TX, USA
    Dermatol Clin 20:749-61. 2002
  4. ncbi request reprint Long-term management of plaque psoriasis with continuous efalizumab therapy
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 54:S182-8. 2006
  5. ncbi request reprint The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy
    Alan Menter
    Baylor University Medical Center, Texas Dermatology Associates, 5310 Harvest Hill Road, Suite 260, Dallas, TX 75230, USA
    J Cutan Med Surg 8:20-5. 2004
  6. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 60:643-59. 2009
  7. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 58:826-50. 2008
  8. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions
    Alan Menter
    Psoriasis Research Center, Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 65:137-74. 2011
  9. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 61:451-85. 2009
  10. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy
    Alan Menter
    Psoriasis Research Center, Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 62:114-35. 2010

Detail Information

Publications90

  1. ncbi request reprint Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    Int J Dermatol 46:637-48. 2007
    ..To prevent rebound on discontinuation of efalizumab, this study evaluated the effectiveness of transitioning patients to an alternative psoriasis therapy...
  2. ncbi request reprint The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 54:61-3. 2006
    ..30 [1.26-4.19]). Alefacept provided incremental efficacy over 5 successive 12-week treatment courses...
  3. ncbi request reprint Update on botulinum toxin for facial aesthetics
    Jennifer Clay Cather
    Texas Dermatology Research Institute, Baylor Medical University, Dallas, TX, USA
    Dermatol Clin 20:749-61. 2002
    ..It is likely that the use of specific measuring devices, such as digital imaging, will further help define the use of botulinum toxin for different muscle groups and facial aesthetic indications...
  4. ncbi request reprint Long-term management of plaque psoriasis with continuous efalizumab therapy
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 54:S182-8. 2006
  5. ncbi request reprint The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy
    Alan Menter
    Baylor University Medical Center, Texas Dermatology Associates, 5310 Harvest Hill Road, Suite 260, Dallas, TX 75230, USA
    J Cutan Med Surg 8:20-5. 2004
    ..Alefacept helps fulfill the needs of psoriasis patients by providing efficacy, safety, off-treatment remissions, and improvement in QOL...
  6. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 60:643-59. 2009
    ....
  7. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 58:826-50. 2008
    ..Finally, we will discuss the safety and efficacy of the biologic treatments used to treat patients with psoriasis...
  8. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions
    Alan Menter
    Psoriasis Research Center, Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 65:137-74. 2011
    ..In addition, we will update the prior 5 guidelines and address gaps in research and care that currently exist, while making suggestions for further studies that could be performed to help address these limitations in our knowledge base...
  9. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 61:451-85. 2009
    ..We will also briefly discuss the available data for the use of azathioprine, fumaric acid esters, hydroxyurea, leflunomide, mycophenolate mofetil, sulfasalazine, tacrolimus, and 6-thioguanine in psoriasis...
  10. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy
    Alan Menter
    Psoriasis Research Center, Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 62:114-35. 2010
    ..Finally, where available, we will summarize the available data that compare the safety and efficacy of the different forms of UV light therapy...
  11. ncbi request reprint Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis
    Alan Menter
    Baylor Research Institute, Dallas, TX, USA
    J Drugs Dermatol 8:52-7. 2009
    ..003). Adverse events were reported by less than one-third of patients from each treatment group (31% for CP spray and 33% for C-BD ointment)...
  12. ncbi request reprint An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasis
    Alan Menter
    Baylor Research Institute, Dallas, Texas, USA
    Cutis 88:46-51. 2011
    ..05% treatment in the morning and calcitriol ointment 3 microg/g in the evening is efficacious and without unexpected safety issues for the management of moderate plaque psoriasis...
  13. ncbi request reprint Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations
    Alan Menter
    Psoriasis Research Unit, Baylor Research Institute, Dallas, TX, USA
    J Drugs Dermatol 7:1137-46. 2008
    ..Infliximab is indicated for severe plaque psoriasis (PsO). The investigators compared safety event rates in infliximab PsO trials with those of the general United States and PsO populations...
  14. doi request reprint Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials
    Caitriona Ryan
    Department of Dermatology, Baylor Research Institute, 3900 Junius St, Ste 125, Dallas, TX 75246, USA
    JAMA 306:864-71. 2011
    ..Preliminary reports of major adverse cardiovascular events (MACEs) in psoriasis patients receiving anti-IL-12/23 agents have prompted concern...
  15. doi request reprint Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis
    Alan Menter
    Baylor Psoriasis Research Institute, Baylor University Medical Center, Dallas, TX 75246, USA
    J Am Acad Dermatol 63:448-56. 2010
    ....
  16. ncbi request reprint Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade
    Laura Winterfield
    Department of Dermatology, University of Texas Southwestern Medical School, Dallas, TX, USA
    Dermatol Clin 22:437-47, ix. 2004
    ..Comprehensive evaluation in controlled trials may allow infliximab to take its place among the expanding group of biologic drugs for the treatment of moderate to severe psoriasis...
  17. ncbi request reprint Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy
    Qurat Ul Ain Kamili
    Baylor Research Institute, Dallas, TX 75246, USA
    J Drugs Dermatol 9:57-60. 2010
    ..In addition, the authors emphasize the role of a multi-disciplinary approach and appropriate coordination among caregivers...
  18. ncbi request reprint Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial
    Alan Menter
    Dermatology Department, Baylor University Medical Center, Dallas, TX, USA
    J Drugs Dermatol 12:92-8. 2013
    ....
  19. doi request reprint Cutaneous manifestations of gastrointestinal disease: Part II
    Breck Thrash
    Division of Dermatology, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas
    J Am Acad Dermatol 68:211.e1-211.e33. 2013
    ..These conditions are reviewed with updates on theĀ genetic basis, diagnostic and screening modalities, and therapeutic options. Finally, GI complications associated with vascular disorders will also be discussed...
  20. ncbi request reprint Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis
    Alan Menter
    Baylor University Medical Center, Dallas, TX, USA
    Arch Dermatol 141:31-8. 2005
    ..To assess the efficacy and safety of a 24-week course of efalizumab...
  21. ncbi request reprint Combining traditional agents and biologics for the treatment of psoriasis
    Jennifer Clay Cather
    Baylor University Medical Center, Dallas, TX, USA
    Semin Cutan Med Surg 24:37-45. 2005
    ..A review of the literature, plus our personal experience in using combinations of traditional agents and biologics, is presented...
  22. ncbi request reprint Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    Alan Menter
    Division of Dermatology, Baylor Research Institute, University of Texas Southwestern Medical School, 3900 Junius St, 125, Dallas, TX 75246 1613, USA
    J Am Acad Dermatol 58:106-15. 2008
    ..Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor, a key proinflammatory cytokine involved in the pathogenesis of psoriasis...
  23. ncbi request reprint Current and future management of psoriasis
    Alan Menter
    Baylor Research Institute and Southwestern Medical School, Dallas, Texas 75246, USA
    Lancet 370:272-84. 2007
    ..Other innovative treatments are undergoing clinical studies, with the aim of maintaining safe, long-term control of the condition...
  24. ncbi request reprint The status of biologic therapies in the treatment of moderate to severe psoriasis
    Alan Menter
    Psoriasis Research Unit, Baylor Research Institute, Dallas, Texas, USA
    Cutis 84:14-24. 2009
    ..Prospective trials of this sort are therefore needed to better understand the potential risks and benefits of such approaches...
  25. ncbi request reprint Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis
    Alan Menter
    Baylor Medical Center, Dallas, Texas, USA
    J Drugs Dermatol 3:27-38. 2004
    ....
  26. doi request reprint The use of cyclosporine in dermatology: part II
    Caitriona Ryan
    Department of Dermatology at Baylor University Medical Center, Dallas, Texas 75246, USA
    J Am Acad Dermatol 63:949-72; quiz 973-4. 2010
    ....
  27. ncbi request reprint Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review
    Qurat Ul Ain Kamili
    Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA
    J Drugs Dermatol 10:539-44. 2011
    ....
  28. ncbi request reprint Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab
    Jennifer Clay Cather
    Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas, USA
    Expert Opin Biol Ther 3:361-70. 2003
    ....
  29. ncbi request reprint Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis
    Amy Perlmutter
    Baylor Research Institute, Dallas, Texas 75246, USA
    J Am Acad Dermatol 58:116-24. 2008
    ..A proportion of patients responding to therapy have been reported to experience remissions of approximately 7 to 8 months, characterized by disease-free and treatment-free intervals...
  30. ncbi request reprint A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis
    Alan Menter
    Division of Dermatology, Baylor University Medical Center, UT Southwestern Medical School, 5310 Harvest Hill Rd, Ste 260, Dallas, TX 75230, USA
    J Am Acad Dermatol 56:31.e1-15. 2007
    ..Previous studies of infliximab in psoriasis have demonstrated rapid improvement with induction therapy and sustained response with regularly administered maintenance therapy...
  31. ncbi request reprint Relapse, rebound, and psoriasis adverse events: an advisory group report
    Wayne Carey
    Royal Victoria Hospital, Montreal, Quebec, Canada
    J Am Acad Dermatol 54:S171-81. 2006
    ....
  32. doi request reprint The use of cyclosporine in dermatology: part I
    Karrie T Amor
    Department of Dermatology at the University of Texas, Houston, Texas, USA
    J Am Acad Dermatol 63:925-46; quiz 947-8. 2010
    ....
  33. ncbi request reprint Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial
    Alan Menter
    Baylor Psoriasis Research Center, Baylor Research Institute, Dallas, Texas, USA
    Cutis 80:12-9. 2007
    ..Based on these data, clobetasol propionate spray 0.05% is an effective and convenient topical monotherapy for moderate to severe plaque psoriasis...
  34. ncbi request reprint Efalizumab: continuous therapy for chronic psoriasis
    Jennifer Clay Cather
    Baylor University Medical Center, 5310 Harvest Hill Rd, Ste 260, Dallas, TX75230, USA
    Expert Opin Biol Ther 5:393-403. 2005
    ..Efalizumab may thus potentially offer patients a safe option for long-term safe control in managing their disease...
  35. doi request reprint The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis
    Caitriona Ryan
    Department of Dermatology, Baylor Research Institute, Dallas, Texas, USA
    Mol Diagn Ther 14:81-93. 2010
    ....
  36. doi request reprint The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial
    Alan Menter
    Baylor Psoriasis Research Institute, Dallas, TX, USA
    J Am Acad Dermatol 62:812-8. 2010
    ..Psoriasis is associated with health-related quality-of-life impairment and depression...
  37. ncbi request reprint Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial
    Kenneth B Gordon
    Loyola University Medical Center, Maywood, Ill 60153, USA
    JAMA 290:3073-80. 2003
    ..Because T-cell interactions are involved in the pathophysiology of psoriasis, therapy with a T-cell modulator may have beneficial effects on psoriasis severity and health-related quality of life (HRQL)...
  38. ncbi request reprint Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial
    Kim A Papp
    Probity Medical Research, Waterloo, Ontario, Canada
    Int J Dermatol 45:605-14. 2006
    ..To provide safety data for efalizumab, a recombinant humanized monoclonal IgG(1) antibody, in adults with chronic plaque psoriasis...
  39. ncbi request reprint Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis
    Alan Menter
    Baylor Psoriasis Research Center, Baylor Research Institute, Baylor University Medical Center, 3900 Junius St, Ste 145, Dallas, TX 75246, USA
    Cutis 89:89-94. 2012
    ..05%. Clobetasol propionate spray 0.05% is a topical product with a documented efficacy and safety profile with good acceptability in patients with moderate to severe plaque psoriasis...
  40. doi request reprint Topical treatment of psoriasis
    Qurat Ul Ain Kamili
    Psoriasis Research Unit, Baylor Research Institute, Dallas, Texas, USA
    Curr Probl Dermatol 38:37-58. 2009
    ..This will help alleviate the common problem of poor patient adherence, and inevitably result in more optimal clinical outcomes...
  41. ncbi request reprint Practical considerations in future psoriasis therapies
    Christy Riddle
    Department of Internal Medicine, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Dermatol Clin 22:487-92, x. 2004
    ..Several tiers of psoriasis care are outlined to encourage individual physicians to choose the optimum level of service compatible with their individual practices...
  42. ncbi request reprint Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy
    Nick J Lowe
    Clinical Research Specialists, Santa Monica, California, USA
    Int J Dermatol 42:224-30. 2003
    ..This open-label study evaluated the safety and tolerability, efficacy, and pharmacodynamics of repeat courses of alefacept in men and women with chronic plaque psoriasis. This article reports the interim results of this ongoing study...
  43. doi request reprint Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial
    Alexa B Kimball
    Clinical Unit for Research Trials in Skin CURTIS, Massachusetts General and Brigham and Women s Hospitals, Harvard Medical School, 50 Staniford St, No 246, Boston, MA 02114, USA
    Arch Dermatol 144:200-7. 2008
    ..To investigate the efficacy and safety of ABT-874, an interleukin 12/23 monoclonal antibody, in psoriasis...
  44. doi request reprint Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis
    Dennis A Revicki
    Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD 20814, USA
    Dermatology 216:260-70. 2008
    ..However, the association between HRQOL outcomes and more substantial degrees of Psoriasis Area and Severity Index (PASI) response and physician and patient global ratings remains ill defined...
  45. ncbi request reprint Infliximab
    Laura S Winterfield
    Department of Dermatology, University of Texas Southwestern Medical School, Dallas, Texas, USA
    Dermatol Ther 17:409-26. 2004
    ..Practical issues such as patient selection, monitoring, cost, and potential combination therapies are also discussed...
  46. ncbi request reprint Changing paradigms in dermatology: nuclear hormone receptors
    Laura Winterfield
    Department of Dermatology University of Texas Southwestern Medical School, Dallas, Texas 75390 7208, USA
    Clin Dermatol 21:447-54. 2003
    ..The current understanding of NHRs and future directions for NHR ligands in dermatology are discussed...
  47. ncbi request reprint Rationale for the use of topical corticosteroids in melasma
    Alan Menter
    Division of Dermatology, Baylor University Medical Center, Dallas, Texas, USA
    J Drugs Dermatol 3:169-74. 2004
    ..01% suppresses biosynthetic and secretory functions of melanocytes, and thus melanin production, leading to early response in melasma, synergy among the three agents, and no significant side effects over an 8-week period...
  48. ncbi request reprint Case studies in severe psoriasis: A clinical strategy
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, 1 Gustave Levy Place, Box 1047, New York, NY 10029 6574, USA
    J Dermatolog Treat 14:26-46. 2003
    ..The purpose of the algorithms is to make optimum use of phototherapy, traditional cytotoxic and immunosuppressive agents, retinoids, and newer biologic agents...
  49. ncbi request reprint Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial
    Craig L Leonardi
    Saint Louis University School of Medicine, St Louis, Missouri, USA
    J Am Acad Dermatol 52:425-33. 2005
    ..Efalizumab inhibits multiple T-cell-mediated processes...
  50. ncbi request reprint Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901 0019, USA
    Clin Immunol 111:28-37. 2004
    ..Reduction in lesional, activated T cells induces improvement in psoriatic plaques. Galiximab (IDEC-114), an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation...
  51. ncbi request reprint Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes
    Leon Kircik
    Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA
    J Drugs Dermatol 7:245-53. 2008
    ..Etanercept and narrow-band ultraviolet light B (NB-UVB) are widely used to treat this disease...
  52. ncbi request reprint Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial
    Alice B Gottlieb
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    J Am Acad Dermatol 51:534-42. 2004
    ..Tumor necrosis factor-alpha is a key mediator in the pathogenesis of psoriasis. Infliximab is a monoclonal antibody that specifically binds to tumor necrosis factor-alpha, blocking its biologic activity...
  53. doi request reprint Cutaneous manifestations of gastrointestinal disease: Part I
    Kejal R Shah
    Division of Dermatology, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas
    J Am Acad Dermatol 68:189.e1-189.e21. 2013
    ..This underscores the important role of dermatologists in the diagnosis, detection, monitoring, and treatment of these disorders while consulting and interacting with their GI colleagues...
  54. pmc Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter
    Alan Menter
    Baylor Research Institute, Dallas, Texas, USA
    J Pharmacol Exp Ther 342:696-708. 2012
    ..Collectively, our results demonstrate a strong in vitro-in vivo correlation implicating stereoselective transport by PCFT as the mechanism underlying stereoselective absorption observed in vivo...
  55. doi request reprint Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management
    Amanda Abramson
    Division of Dermatology, Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 67:1349-61. 2012
    ..Tumor necrosis factor inhibitory agents are currently considered to be contraindicated in psoriatic patients with hepatitis B...
  56. doi request reprint Current investigational drugs in psoriasis
    Caitriona Ryan
    Department of Dermatology, Baylor University Medical Center, 3900 Junius Street, Suite 125, Dallas, TX 75204, USA
    Expert Opin Investig Drugs 21:473-87. 2012
    ..Proven long-term safety, however, is an absolute necessity with newly developed drugs, and should, therefore, still be considered second-line agents to current established treatments with long-term safety data...
  57. doi request reprint Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool
    Elizabeth Farley
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 60:1024-31. 2009
    ..Palmoplantar psoriasis is associated with significant quality-of-life issues. Its epidemiology and phenotypical expression remain ill defined...
  58. ncbi request reprint One-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratoses
    Alan Menter
    Baylor University Medical Center, Division of Dermatology, Dallas, TX 75246, USA
    Cutis 81:509-16. 2008
    ..Using this short treatment duration period in combination with cryosurgery may prove beneficial in clinical practice. Extending treatment for up to 4 weeks will further improve AK lesion clearance rates...
  59. doi request reprint Comorbidities in psoriasis patients
    Noori Kim
    University of Texas Southwestern, Dallas, TX
    Semin Cutan Med Surg 29:10-5. 2010
    ..Psoriasis, with its comorbidities, must be approached in a multidisciplinary manner to effectively and comprehensively understand, manage, and treat those with this complex disorder...
  60. ncbi request reprint PsEma--a hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczema
    William Abramovits
    Department of Dermatology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    Skinmed 4:275-81. 2005
    ..The authors have observed significant overlap between these two conditions such that a distinction between them may not always be made, even with histologic examination of skin biopsy specimens...
  61. ncbi request reprint Efficacy and safety of a new triple-combination agent for the treatment of facial melasma
    Susan C Taylor
    Dermatology Associates, St Luke s Roosevelt Hospital, New York, New York 10025, USA
    Cutis 72:67-72. 2003
    ..The most common adverse reactions seen with all treatment groups were erythema, skin peeling, burning, and/or stinging sensation. The majority of treatment-related adverse events were of mild severity...
  62. ncbi request reprint A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis
    Christopher S Carlin
    Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA
    J Am Acad Dermatol 50:859-66. 2004
    ..We conclude that PASI 50 equates to a clinically meaningful improvement in psoriasis and represents a discerning primary endpoint...
  63. ncbi request reprint Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study
    Carin Gribetz
    Mt Sinai School of Medicine, Department of Dermatology, New York, New York, USA
    J Am Acad Dermatol 51:731-8. 2004
    ..Pimecrolimus, a well-tolerated, nonatrophogenic, skin-selective inflammatory cytokine inhibitor, has been shown to be effective in the treatment of psoriasis when applied topically under occlusion...
  64. ncbi request reprint Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Drugs Dermatol 6:428-35. 2007
    ..Calcitriol 3 microg/g ointment has demonstrated good clinical efficacy as well as topical and systemic safety when used to treat psoriasis...
  65. ncbi request reprint Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis
    Dennis A Revicki
    Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Avenue, Bethesda, MD 20814, USA
    J Dermatolog Treat 18:341-50. 2007
    ..The effect of adalimumab on patient-reported outcomes (PROs) was evaluated in patients with moderate to severe psoriasis during the initial 16-week, double-blind period of a 52-week, Phase III, multicenter trial...
  66. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics
    Alice Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    J Am Acad Dermatol 58:851-64. 2008
    ..We will discuss the use of disease-modifying antirheumatic drugs and the biologic therapies in the treatment of patients with moderate to severe psoriatic arthritis...
  67. ncbi request reprint A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis
    Craig L Leonardi
    St Louis University School of Medicine, St Louis, MO 63117, USA
    Dermatology 213:204-14. 2006
    ..Efalizumab is a recombinant monoclonal immunoglobulin G1 (IgG1) antibody approved for use in psoriasis patients...
  68. doi request reprint The use of ustekinumab in autoimmune disease
    Caitriona Ryan
    Baylor Research Institute, Department of Dermatology, 3900 Junius Street, Suite 1125, Dallas, Texas 75204, USA
    Expert Opin Biol Ther 10:587-604. 2010
    ..Ustekinumab is an antibody to the common p40 subunit of IL-12 and IL-23, which has been studied in the treatment of psoriasis, psoriatic arthritis, Crohn's disease and multiple sclerosis...
  69. doi request reprint The ethics of consulting with pharmaceutical companies
    Andrew Miner
    The University of Texas Southwestern, Dallas, TX, USA
    Clin Dermatol 27:339-45. 2009
    ..These include publication and prescribing bias. These also lead to the real or apparent conflict of interest when the consultant receives unearned, unjustified, or excessive compensation and gifts...
  70. ncbi request reprint Novel therapies for psoriasis
    Jennifer Cather
    Baylor University Medical Center, Dallas, Texas, USA
    Am J Clin Dermatol 3:159-73. 2002
    ..For the 2 to 3% of the worldwide population of patients with psoriasis the future has never looked brighter...
  71. ncbi request reprint Cardiocutaneous syndromes and associations
    Nagla F Abdelmalek
    Division of Dermatology and Cardiology, Department of Internal Medicine, Baylor University Medical Center, Dallas, TX, USA
    J Am Acad Dermatol 46:161-83; quiz 183-6. 2002
    ....
  72. ncbi request reprint A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis
    Mark Lebwohl
    Departments of Dermatology, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Int J Dermatol 41:269-74. 2002
    ..A clobetasol propionate foam product is as effective as clobetasol propionate solution in the treatment of scalp psoriasis...
  73. ncbi request reprint Ciclopirox gel in the treatment of patients with interdigital tinea pedis
    Raza Aly
    Department of Dermatology, University of California San Francisco, USA
    Int J Dermatol 42:29-35. 2003
    ..Ciclopirox, a broad-spectrum hydroxypyridone antifungal, has proven efficacy against the organisms commonly implicated in tinea pedis; Trichophyton rubrum, T.mentagrophytes and Epidermophyton floccosum...
  74. ncbi request reprint A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis
    Cynthia Helms
    Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Nat Genet 35:349-56. 2003
    ..This is the second example of loss of a RUNX1 binding site associated with susceptibility to an autoimmune disease. It also suggests defective regulation of SLC9A3R1 or NAT9 by RUNX1 as a susceptibility factor for psoriasis...
  75. ncbi request reprint Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts
    Kenneth B Gordon
    Department of Medicine, Division of Dermatology, Loyola University Medical Center, Maywood, IL 60153, USA
    Arch Dermatol 139:1563-70. 2003
    ..To examine the relationship between the pharmacodynamic and antipsoriatic effects of alefacept, a biologic agent that targets CD4+ and CD8+ memory T cells...
  76. ncbi request reprint Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array
    Xianghong Zhou
    Department of Biostatistics, Harvard University, Boston 02115, USA
    Physiol Genomics 13:69-78. 2003
    ....
  77. ncbi request reprint Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris
    Joel Schlessinger
    Advanced Skin Research Center, Omaha, NE, USA
    J Drugs Dermatol 6:607-15. 2007
    ..Individual ingredients and the combination were well-tolerated. Among those treated with the combination formulation, discontinuation rates due to adverse events were 1% or less...
  78. ncbi request reprint Decision points for the initiation of systemic treatment for psoriasis
    Steven R Feldman
    Department of Dermatology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1071, USA
    J Am Acad Dermatol 53:101-7. 2005
    ....
  79. ncbi request reprint Tazarotene versus tazarotene plus hydroquinone in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized study
    Nicholas Lowe
    UCLA School of Medicine, Santa Monica, CA, USA
    J Cosmet Laser Ther 8:121-7. 2006
    ..To compare the efficacy and tolerability of tazarotene plus hydroquinone versus tazarotene alone in the treatment of facial photodamage...
  80. doi request reprint Rethinking eligibility creep
    Maryanne Kazanis
    J Am Acad Dermatol 59:165-7; author reply 167. 2008
  81. ncbi request reprint Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne
    John J DiGiovanna
    Division of Dermatopharmacology, Department of Dermatology, Brown Medical School Rhode Island Hospital, Providence, RI 02903, USA
    J Am Acad Dermatol 51:709-17. 2004
    ..The effect of short-term (4-5 months) therapy at the lower dose recommended for acne on bone development in younger, growing adolescent (12-17 years) patients has not been well studied...
  82. ncbi request reprint Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis
    Frank C Victor
    Clinical Research Center, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA
    Clin Dermatol 21:392-7. 2003
    ..The role of TNF-alpha in the pathogenesis of psoriasis is reviewed, along with clinical trials demonstrating the efficacy of new anti-TNF-alpha immunobiologics in the treatment of psoriasis and psoriatic arthritis...
  83. ncbi request reprint Combination therapy to treat moderate to severe psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, Mt Sinai Medical Center, 5 E 98th Street, 12th Floor, New York, NY 10029 6574, USA
    J Am Acad Dermatol 50:416-30. 2004
    ....
  84. ncbi request reprint Ciclopirox gel for seborrheic dermatitis of the scalp
    Raza Aly
    Department of Dermatology, University of California San Francisco, San Francisco, CA, USA
    Int J Dermatol 42:19-22. 2003
    ..Typically, sites dense with sebaceous glands support growth of the lipophilic yeast Malassezia furfur. Ciclopirox (Loprox) gel is a hydroxypyridone, broad-spectrum antifungal agent proven effective against the yeast M. furfur...
  85. ncbi request reprint A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads
    Helen Torok
    Trillium Creek Dermatology, Inc, Medina, OH 44526, USA
    J Drugs Dermatol 4:592-7. 2005
    ..Once daily application of TC cream applied intermittently over a long period is a safe, tolerable, and effective treatment for moderate to severe melasma of the face...
  86. ncbi request reprint Psoriasis and the metabolic syndrome
    Alice B Gottlieb
    Tufts Medical Center, Boston, MA 02111 1533, USA
    J Drugs Dermatol 7:563-72. 2008
    ..This article reviews the association of psoriasis with metabolic syndrome, as well as the impact of biologic agents that are currently used to treat psoriasis (ie, TNF antagonists) on risk factors for metabolic syndrome...
  87. ncbi request reprint AAD consensus statement on psoriasis therapies
    Jeffrey P Callen
    J Am Acad Dermatol 49:897-9. 2003
  88. ncbi request reprint Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR
    Cynthia Helms
    Department of Genetics, Washington University School of Medicine, Box 8232, 4566 Scott Avenue, St Louis, Missouri, 63110, USA
    Hum Genet 118:466-76. 2005
    ..The introduction of a potential binding site for the RUNX/AML family of transcription factors in intron 7, is also specific to these HLA-C alleles. These variants need to be investigated further for their role as PSORS1...
  89. pmc A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci
    Ying Liu
    Division of Human Genetics, Department of Genetics, Washington University School of Medicine, St Louis, Missouri, United States of America
    PLoS Genet 4:e1000041. 2008
    ..This region harbors the interleukin 2 (IL2) and interleukin 21 (IL21) genes and was recently shown to be associated with four autoimmune diseases (Celiac disease, Type 1 diabetes, Grave's disease and Rheumatoid Arthritis)...
  90. ncbi request reprint Definitions of measures of effect duration for psoriasis treatments
    Kenneth B Gordon
    Arch Dermatol 141:82-4. 2005